CN115591008A - 一种喷涂式液体护创敷料及其制备方法 - Google Patents
一种喷涂式液体护创敷料及其制备方法 Download PDFInfo
- Publication number
- CN115591008A CN115591008A CN202111663083.9A CN202111663083A CN115591008A CN 115591008 A CN115591008 A CN 115591008A CN 202111663083 A CN202111663083 A CN 202111663083A CN 115591008 A CN115591008 A CN 115591008A
- Authority
- CN
- China
- Prior art keywords
- extract
- portions
- parts
- spray
- liquid wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920001661 Chitosan Polymers 0.000 claims abstract description 33
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 31
- 239000008213 purified water Substances 0.000 claims abstract description 29
- OLZAGZCCJJBKNZ-UHFFFAOYSA-N formaldehydephenlyl-O-beta-D-pyranosyl alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940072056 alginate Drugs 0.000 claims abstract description 23
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 23
- 229920000615 alginic acid Polymers 0.000 claims abstract description 23
- 241001474374 Blennius Species 0.000 claims abstract description 22
- 229940119217 chamomile extract Drugs 0.000 claims abstract description 22
- 235000020221 chamomile extract Nutrition 0.000 claims abstract description 22
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 21
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 9
- OLZAGZCCJJBKNZ-UJPOAAIJSA-N 4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-UJPOAAIJSA-N 0.000 claims abstract 5
- 238000003756 stirring Methods 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 26
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 14
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 235000010413 sodium alginate Nutrition 0.000 claims description 12
- 239000000661 sodium alginate Substances 0.000 claims description 12
- 229940005550 sodium alginate Drugs 0.000 claims description 12
- -1 terpene lactone Chemical class 0.000 claims description 9
- 235000007586 terpenes Nutrition 0.000 claims description 9
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 8
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 7
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 7
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical class [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical class [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- 241000218628 Ginkgo Species 0.000 claims 5
- 239000007921 spray Substances 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 41
- 208000027418 Wounds and injury Diseases 0.000 abstract description 41
- 244000194101 Ginkgo biloba Species 0.000 abstract description 18
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 230000029663 wound healing Effects 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000740 bleeding effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 230000023597 hemostasis Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000000474 nursing effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- OLZAGZCCJJBKNZ-SYLRKERUSA-N Helicid Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=O)C=C1 OLZAGZCCJJBKNZ-SYLRKERUSA-N 0.000 description 27
- 230000005856 abnormality Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 7
- 241000195474 Sargassum Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000001223 reverse osmosis Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 238000004821 distillation Methods 0.000 description 4
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000504663 Andrena nippon Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241001677302 Hylocereus Species 0.000 description 1
- 241001596954 Larimichthys Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000208465 Proteaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229910021643 water for pharmaceutical use Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及液体护创敷料(IPC分类号:A61K31/00),尤其涉及一种喷涂式液体护创敷料及其制备方法。按重量份计,原料至少包含:羧甲基壳聚糖5~10份,海藻酸盐0.2~5份,纯化水30~60份,乙醇5~10份,银杏提取物1~6份,海藻提取物1~5份,春黄菊提取物0.2~5份,豆腐果苷1~3份。因此,本发明制备的液体护创敷料是一种生物相容性好,安全性、防粘连、抗菌、止血、促进创口愈合等优点的新型护理材料,同时形成可溶性生物薄膜,兼具“物理抗菌”和“隐形纱布”的双重功效且附着力强,不仅可以长效抗菌,同时还可以阻隔伤口与环境接触,预防外界感染,无需包扎,使用方便有效,抗菌效炎,快速修复,止血止痛,促进创口的愈合。
Description
技术领域
本发明涉及液体护创敷料(IPC分类号:A61K31/00),尤其涉及一种喷涂式液体护创敷料及其制备方法。
背景技术
传统敷料如各种纱布、棉垫等是目前临床上使用的主要敷料,传统敷料成本低,原料来源广泛,质地柔软,有较强的吸收能力并可防止创面渗液积聚,对创面有一定的保护作用,至今仍在各种类型的创伤中广泛应用。但随着对伤口愈合的进一步理解和要求,传统敷料已日益显出它的局限性,如对创面愈合无促进作用,无保湿作用,肉芽组织容易长入纱布网眼中致粘连结痂,且敷料渗透时易导致外源性感染等。低端敷料已经不能完全满足人们越来越高的生活需要,而喷涂式液体护创敷料的研究和发展正迫在眉睫,同时具有较广的市场和前景。
因此,本发明制备的液体护创敷料是一种生物相容性好,安全性、防粘连、抗菌、止血、促进创口愈合等优点的新型护理材料,同时形成可溶性生物薄膜,兼具“物理抗菌”和“隐形纱布”的双重功效且附着力强,不仅可以长效抗菌,同时还可以阻隔伤口与环境接触,预防外界感染,无需包扎,使用方便有效,抗菌效炎,快速修复,止血止痛,促进创口的愈合。
发明内容
为了解决上述问题,本发明的第一方面提供了一种喷涂式液体护创敷料,按重量份计,原料至少包含:羧甲基壳聚糖5~10份,海藻酸盐0.2~5份,纯化水30~60份,乙醇5~10份,银杏提取物1~6份,海藻提取物1~5份,春黄菊提取物0.2~5份,豆腐果苷1~3份。
作为一种优选的方案,所述羧甲基壳聚糖6~8份,海藻酸盐1~4份,纯化水40~50份,乙醇6~8份,银杏提取物2~4份,海藻提取物2~4份,春黄菊提取物1~4份,豆腐果苷1~3份。
羧甲基壳聚糖
羧甲基壳聚糖因其具有生物相容性好、粘附性好、抗菌消炎、促进伤口愈合等优点,因此在临床具有广泛的应用,目前包括壳聚糖基可吸收止血非织布、外科手术用防粘连液等近10款3类医疗器械产品获得CFDA批准上市。羧甲基壳聚糖中的氨基带正电,可以与表面带负电的血细胞结合,促进血细胞的迅速粘附和聚集,另外羧甲基壳聚糖吸液后能够形成一层凝胶膜均匀粘附在创伤组织表面,从而发挥全面的止血功能。
作为一种优选的方案,所述羧甲基壳聚糖,海藻酸盐的重量比为(6~8):(1~4)。
作为一种优选的方案,所述羧甲基壳聚糖,海藻酸盐的重量比为7:3。
作为一种优选的方案,所述海藻酸盐为海藻酸钙盐、海藻酸钾盐、海藻酸钠盐的一种或多种。
作为一种优选的方案,所述海藻酸盐为海藻酸钠盐。
银杏叶提取物
银杏提取物为银杏科植物银杏(Ginkgo bilobaL)的干燥叶、根、茎、果、种皮等部位的提取物,含有多种药用成分,其中含几十种黄酮类活性成分、微量元素、氨基酸和生物碱等,主要有效成分包括银杏总黄酮醇苷和萜类内酯等。具有活血化瘀,可拮抗血小板活化因子(PAF),降低血小板聚集,改善血液流变学,抑制血栓形成;清除自由基的生成,抑制细胞膜脂质过氧化,保护细胞膜。
作为一种优选的方案,所述银杏提取物为银杏叶提取物,
作为一种优选的方案,所述银杏叶提取物的总黄酮甙重量含量23~25%,萜内酯含量5~7%。
作为一种优选的方案,所述银杏叶提取物的总黄酮甙质量含量24%,萜内酯质量含量6%。
作为一种优选的方案,所述银杏叶提取物,购买自北京中检航标生物有限公司。
海藻提取物
海藻提取物具有抗菌消炎、防止皮肤感染和过敏性皮炎等功效;此外,海藻中所含的碘亦具有抑菌消毒作用,有效遏制慢频率神经冲动引起的瘙痒;海藻多糖对HIV、HSV、囊膜病毒、沙粒病毒、流感病毒、巨细胞病毒、反转录病毒及棒状病毒等多种病毒具有明显的抑制作用。
作为一种优选的方案,所述海藻提取物购买自西安超邦生物科技有限公司。
作为一种优选的方案,所述海藻提取物,银杏叶提取物的重量比为1:1。
豆腐果苷
豆腐果苷(Hilicidum)化学名为对苯甲醛-β-D-阿洛吡喃糖,是中国科学院昆明植物研究所最先从山龙眼科山龙眼属萝卜树(HeliciaerraticaHook(Proteaceae))的果实中提取的有效成分。由云南省卫生厅组织鉴定并于1983年审批,为地标转国标品种。
本发明中的纯化水,是指纯水通过蒸馏法、离子交换法、反渗透法或其他适宜的方法制得的供药用的水,不含任何添加剂。
作为一种优选的方案,所述豆腐果苷的CAS号为80154-34-3,可市售,例如成都格普特生物科技有限公司。
作为一种优选的方案,所述春黄菊提取物,豆腐果苷的重量份为(1~1.1):1。
作为一种优选的方案,所述乙醇占总质量的8~12%。
本发明的第二方面提供了一种喷涂式液体护创敷料的制备方法,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中25~30℃下搅拌2~3h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸钠盐经恒温65℃-70℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在65~70℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
有益效果:
1.本发明通过羧甲基壳聚糖,海藻酸钠的协同作用,并且当羧甲基壳聚糖,海藻酸钠的重量比为7:3时,对革兰氏阳性菌细菌具有一定的抗菌作用,并有利于保留羧甲基壳聚糖中氨基的生物活性,从而增强止血效果。
2.本发明中的海藻中的活性物质能与皮肤蛋白结合形成保湿性的凝胶,而且它还可以通过水合作用,在皮肤表面形成保护膜,防止水分蒸发。
3.本发明通过限定银杏叶提取物的总黄酮甙质量含量23~25%,萜内酯质量含量5~7%,不仅抗菌、止血、促进创口愈合,同时,也改善了体系中的相容性,从而提高产品的稳定性能。
4.本发明通过限定乙醇占产品总质量的8~12%,提高了产品的稳定性,长期储存不分层,不变色。
5.本发明制备的液体护创敷料预防外界感染,无需包扎,使用方便有效,抗菌效炎,快速修复,止血止痛,促进创口的愈合。
具体实施方式
实施例
实施例1
实施例1提供了一种喷涂式液体护创敷料,按重量份计,原料包含:所述羧甲基壳聚糖7份,海藻酸盐3份,纯化水45份,乙醇7份,银杏叶提取物3份,海藻提取物3份,春黄菊提取物2份,豆腐果苷2份。
本实施例中所述纯化水,是指纯水通过蒸馏法、离子交换法、反渗透法或其他适宜的方法制得的供药用的水,不含任何添加剂。
在本实施例中,所述羧甲基壳聚糖(CAS号:83512-85-0)购买自陕西正一药用辅料有限公司。
在本实施例中,所述海藻酸盐为海藻酸钠盐,购买自西安晋湘药用辅料有限公司。
在本实施例中,所述银杏叶提取物的总黄酮甙质量含量24%,萜内酯质量含量6%,购买自北京中检航标生物有限公司。
在本实施例中,所述海藻提取物购买自西安超邦生物科技有限公司。
在本实施例中,所述春黄菊提取物购买自陕西宝禾生物科技有限公司。
在本实施例中,所述豆腐果苷的CAS号为80154-34-3,购买自成都格普特生物科技有限公司。
本实施例的第二方面提供了一种喷涂式液体护创敷料的制备方法,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中25℃下搅拌2.5h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸盐经恒温65℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在68℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
实施例2
实施例2提供了一种喷涂式液体护创敷料,按重量份计,原料包含:所述羧甲基壳聚糖6份,海藻酸盐1份,纯化水40份,乙醇6份,银杏叶提取物2份,海藻提取物2份,春黄菊提取物1份,豆腐果苷1份。
本实施例中所述纯化水,是指纯水通过蒸馏法、离子交换法、反渗透法或其他适宜的方法制得的供药用的水,不含任何添加剂。
在本实施例中,所述羧甲基壳聚糖(CAS号:83512-85-0)购买自陕西正一药用辅料有限公司。
在本实施例中,所述海藻酸盐为海藻酸钠盐,购买自西安晋湘药用辅料有限公司。
在本实施例中,所述银杏叶提取物的总黄酮甙质量含量24%,萜内酯质量含量6%,购买自北京中检航标生物有限公司。
在本实施例中,所述海藻提取物购买自西安超邦生物科技有限公司。
在本实施例中,所述春黄菊提取物购买自陕西宝禾生物科技有限公司。
在本实施例中,所述豆腐果苷的CAS号为80154-34-3,购买自成都格普特生物科技有限公司。
本实施例的第二方面提供了一种喷涂式液体护创敷料的制备方法,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中25℃下搅拌2.5h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸盐经恒温65℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在68℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
实施例3
实施例3提供了一种喷涂式液体护创敷料,按重量份计,原料包含:所述羧甲基壳聚糖10份,海藻酸盐5份,纯化水60份,乙醇10份,银杏叶提取物6份,海藻提取物5份,春黄菊提取物5份,豆腐果苷3份。
本实施例中所述纯化水,是指纯水通过蒸馏法、离子交换法、反渗透法或其他适宜的方法制得的供药用的水,不含任何添加剂。
在本实施例中,所述羧甲基壳聚糖(CAS号:83512-85-0)购买自陕西正一药用辅料有限公司。
在本实施例中,所述海藻酸盐为海藻酸钠盐,购买自西安晋湘药用辅料有限公司。
在本实施例中,所述银杏叶提取物的总黄酮甙质量含量24%,萜内酯质量含量6%,购买自北京中检航标生物有限公司。
在本实施例中,所述海藻提取物购买自西安超邦生物科技有限公司。
在本实施例中,所述春黄菊提取物购买自陕西宝禾生物科技有限公司。
在本实施例中,所述豆腐果苷的CAS号为80154-34-3,购买自成都格普特生物科技有限公司。
本实施例的第二方面提供了一种喷涂式液体护创敷料的制备方法,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中25℃下搅拌2.5h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸钠盐经恒温65℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在68℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
实施例4
实施例4提供了一种喷涂式液体护创敷料,按重量份计,原料包含:所述羧甲基壳聚糖10份,海藻酸盐5份,纯化水60份,乙醇10份,银杏叶提取物6份,海藻提取物5份,春黄菊提取物5份,豆腐果苷3份。
本实施例中所述纯化水,是指纯水通过蒸馏法、离子交换法、反渗透法或其他适宜的方法制得的供药用的水,不含任何添加剂。
在本实施例中,所述羧甲基壳聚糖(CAS号:83512-85-0)购买自陕西正一药用辅料有限公司。
在本实施例中,所述海藻酸盐为海藻酸钠盐,购买自西安晋湘药用辅料有限公司。
在本实施例中,所述银杏叶提取物的总黄酮甙质量含量24%,萜内酯质量含量6%,购买自北京中检航标生物有限公司。
在本实施例中,所述海藻提取物购买自西安超邦生物科技有限公司。
在本实施例中,所述春黄菊提取物购买自陕西宝禾生物科技有限公司。
在本实施例中,所述豆腐果苷的CAS号为80154-34-3,购买自成都格普特生物科技有限公司。
本实施例的第二方面提供了一种喷涂式液体护创敷料的制备方法,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中30℃下搅拌3h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸钠盐经恒温60℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在65℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
对比例1
对比例1的具体实施方式同对比例1;不同的是,对比例1中未加乙醇。
对比例2
对比例2的具体实施方式同对比例2;不同的是,对比例2的制备方法包括:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中30℃下搅拌3h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸钠盐经恒温40℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在40℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
性能测试:
(1)稳定性:将实施例1~4和对比例1~2中的样品,分别置于50℃下存放3个月进行稳定性考察,评价指标为外观(是否变色,分层)、气味,结果如表1。
性能测试结果:
表1是实施例1~4和对比例1~2所制备液体护创敷料的性能测试结果。
表1
变色 | 分层 | 气味 | |
实施例1 | 无异常 | 无异常 | 无异常 |
实施例2 | 无异常 | 无异常 | 无异常 |
实施例3 | 无异常 | 无异常 | 无异常 |
实施例4 | 无异常 | 无异常 | 无异常 |
对比例1 | 颜色变深 | 分层 | 无异常 |
对比例2 | 颜色变深 | 分层 | 有气味产生 |
Claims (10)
1.一种喷涂式液体护创敷料,其特征在于,按重量份计,原料包含:羧甲基壳聚糖5~10份,海藻酸盐0.2~5份,纯化水30~60份,乙醇5~10份,银杏提取物1~6份,海藻提取物1~5份,春黄菊提取物0.2~5份,豆腐果苷1~3份。
2.根据权利要求1所述的喷涂式液体护创敷料,其特征在于,按重量份计,原料包含:羧甲基壳聚糖6~8份,海藻酸盐1~4份,纯化水40~50份,乙醇6~8份,银杏提取物2~4份,海藻提取物2~4份,春黄菊提取物1~4份,豆腐果苷1~3份。
3.根据权利要求1-2任一项所述的喷涂式液体护创敷料,其特征在于,所述海藻酸盐为海藻酸钙盐、海藻酸钾盐、海藻酸钠盐的一种或多种。
4.根据权利要求3所述的喷涂式液体护创敷料,其特征在于,所述海藻酸盐为海藻酸钠盐。
5.根据权利要求1-2任一项所述的喷涂式液体护创敷料,其特征在于,所述羧甲基壳聚糖,海藻酸盐的重量比为(6~8):(1~4)。
6.根据权利要求1-2任一项所述的喷涂式液体护创敷料,其特征在于,所述银杏提取物为银杏叶提取物。
7.根据权利要求6所述的喷涂式液体护创敷料,其特征在于,所述银杏叶提取物的总黄酮甙质量含量23~25%;所述银杏叶提取物的萜内酯质量含量5~7%。
8.根据权利要求1-2任一项所述的喷涂式液体护创敷料,其特征在于,所述海藻提取物,银杏叶提取物的重量比为1:1。
9.根据权利要求1-2任一项所述的喷涂式液体护创敷料,其特征在于,所述春黄菊提取物,豆腐果苷的重量份为(1~1.1):1。
10.一种根据权利要求1-9任一项所述的喷涂式液体护创敷料的制备方法,其特征在于,主要包括以下步骤:
(1)将总质量1/3的纯化水,乙醇,银杏提取物,海藻提取物,豆腐果苷,羧甲基壳聚糖在搅拌机中25~30℃下搅拌2~3h,混合成液态流体,形成A组份;
(2)将总质量2/3的纯化水,海藻酸盐经恒温65℃-70℃搅拌配置成均匀的混合液态流体,该流体为B组份;
(3)将搅拌好的A组份缓缓加入B组份,在65~70℃恒温下进行搅拌均匀,该流体为C组份;
(4)将春黄菊提取物,银杏提取物,缓缓加入C组份进行恒温搅拌均匀,即得液体护创敷料;
(5)将充分搅拌均匀的液体护创敷料,瓶体灌装、灭菌、检测、包装即为成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111663083.9A CN115591008A (zh) | 2021-12-31 | 2021-12-31 | 一种喷涂式液体护创敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111663083.9A CN115591008A (zh) | 2021-12-31 | 2021-12-31 | 一种喷涂式液体护创敷料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115591008A true CN115591008A (zh) | 2023-01-13 |
Family
ID=84841972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111663083.9A Pending CN115591008A (zh) | 2021-12-31 | 2021-12-31 | 一种喷涂式液体护创敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115591008A (zh) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9421653D0 (en) * | 1994-10-27 | 1994-12-14 | Innovative Tech Ltd | Wound dressing |
CN103520764A (zh) * | 2013-10-29 | 2014-01-22 | 成都迪康中科生物医学材料有限公司 | 功能性敷料及其制备方法和用途 |
CN103908693A (zh) * | 2014-04-15 | 2014-07-09 | 山东颐诺生物科技有限公司 | 一种仿生型海藻酸基复合抗菌敷料及其制备方法 |
CN105641733A (zh) * | 2015-12-29 | 2016-06-08 | 山东康力医疗器械科技有限公司 | 一种复合抗菌止血敷料的制备方法 |
CN106237375A (zh) * | 2016-08-31 | 2016-12-21 | 浙江医鼎医用敷料有限公司 | 一种生物抑菌成膜液体医用敷料及其制备方法 |
CN107583103A (zh) * | 2017-10-23 | 2018-01-16 | 广西信业生物技术有限公司 | 一种止血促愈合液体敷料及其制备方法 |
CN107982571A (zh) * | 2017-12-20 | 2018-05-04 | 张立栋 | 一种抑菌能力强的水胶体敷料及其制备方法 |
CN108126236A (zh) * | 2017-12-20 | 2018-06-08 | 浙江科技学院 | 一种医药涂敷材料及其制备方法 |
CN108498855A (zh) * | 2018-05-09 | 2018-09-07 | 福州大学 | 一种抗菌止血溶胶及其制备方法 |
CN109331219A (zh) * | 2018-11-30 | 2019-02-15 | 广州润虹医药科技股份有限公司 | 一种壳聚糖液体敷料 |
CN110141678A (zh) * | 2019-04-19 | 2019-08-20 | 广东泰宝医疗科技股份有限公司 | 一种藻酸盐理疗液体敷料及其制备方法 |
CN111760067A (zh) * | 2020-06-29 | 2020-10-13 | 华仁药业股份有限公司 | 一种含艾考糊精的组合物及其应用 |
CN112316205A (zh) * | 2020-11-16 | 2021-02-05 | 中国药科大学 | 一种积雪草苷外用凝胶敷料及其制备方法 |
-
2021
- 2021-12-31 CN CN202111663083.9A patent/CN115591008A/zh active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9421653D0 (en) * | 1994-10-27 | 1994-12-14 | Innovative Tech Ltd | Wound dressing |
CN103520764A (zh) * | 2013-10-29 | 2014-01-22 | 成都迪康中科生物医学材料有限公司 | 功能性敷料及其制备方法和用途 |
CN103908693A (zh) * | 2014-04-15 | 2014-07-09 | 山东颐诺生物科技有限公司 | 一种仿生型海藻酸基复合抗菌敷料及其制备方法 |
CN105641733A (zh) * | 2015-12-29 | 2016-06-08 | 山东康力医疗器械科技有限公司 | 一种复合抗菌止血敷料的制备方法 |
CN106237375A (zh) * | 2016-08-31 | 2016-12-21 | 浙江医鼎医用敷料有限公司 | 一种生物抑菌成膜液体医用敷料及其制备方法 |
CN107583103A (zh) * | 2017-10-23 | 2018-01-16 | 广西信业生物技术有限公司 | 一种止血促愈合液体敷料及其制备方法 |
CN107982571A (zh) * | 2017-12-20 | 2018-05-04 | 张立栋 | 一种抑菌能力强的水胶体敷料及其制备方法 |
CN108126236A (zh) * | 2017-12-20 | 2018-06-08 | 浙江科技学院 | 一种医药涂敷材料及其制备方法 |
CN108498855A (zh) * | 2018-05-09 | 2018-09-07 | 福州大学 | 一种抗菌止血溶胶及其制备方法 |
CN109331219A (zh) * | 2018-11-30 | 2019-02-15 | 广州润虹医药科技股份有限公司 | 一种壳聚糖液体敷料 |
CN110141678A (zh) * | 2019-04-19 | 2019-08-20 | 广东泰宝医疗科技股份有限公司 | 一种藻酸盐理疗液体敷料及其制备方法 |
CN111760067A (zh) * | 2020-06-29 | 2020-10-13 | 华仁药业股份有限公司 | 一种含艾考糊精的组合物及其应用 |
CN112316205A (zh) * | 2020-11-16 | 2021-02-05 | 中国药科大学 | 一种积雪草苷外用凝胶敷料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10159762B2 (en) | Hemostatic compositions and dressings for bleeding | |
US10335364B2 (en) | Composition for topical application comprising glycerol and tannins | |
CN109568643B (zh) | 一种含小檗碱的抗菌止血微球的制备方法及其应用 | |
CN103263434B (zh) | 一种创口冲洗、外科手术用防粘连液及制备方法和应用 | |
US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
CN101927027A (zh) | 壳聚糖/羧甲基壳聚糖快速止血海绵及其制备方法 | |
CN114369441A (zh) | 一种多酚基医用组织胶黏剂、制备方法及应用 | |
CN111097067A (zh) | 一种促伤口快速愈合的抗菌性医用敷料及其制备方法 | |
CN104971377A (zh) | 一种液体创口胶及制备方法 | |
CN110859989B (zh) | 一种液体创可贴及其制备方法 | |
CN110935056A (zh) | 一种高吸湿性藻酸盐敷料制备方法 | |
CN110124082A (zh) | 基于马齿苋多糖及黄酮提取物的溶胀型医用生物凝胶填料 | |
CN111012945B (zh) | 一种防水中药液体创可贴及其制备方法 | |
CN115591008A (zh) | 一种喷涂式液体护创敷料及其制备方法 | |
EP3656404A1 (en) | Film for topical use for treating skin lesions and method for producing and applying same | |
Shin et al. | Rational Design and Testing of Antibacterial Aloe Vera Hemostatic Hydrogel | |
CN108553681A (zh) | 一种止血医用敷料及其制备方法 | |
JP2018109032A (ja) | グリセロールとタンニンを含む局所適用のための組成物 | |
CN108404193B (zh) | 白及止血绷带产品及其制备方法 | |
CN117298329A (zh) | 一种壳聚糖创面止血促愈敷料组合物及其制备方法 | |
WO2024123259A1 (en) | New polymer-based hemostatic formulations provided with anti microbial, anti-viral and anti-inflammatory properties and production method thereof | |
RO138080A2 (ro) | Hidrogel cu acţiune hemostatică utilizabil în cazul plăgilor hemoragice | |
WO2024079613A1 (en) | Functionalised polymer material pad for treating skin cavity wounds | |
CN116983463A (zh) | 一种水凝胶创口敷料及其制备方法 | |
CN116139320A (zh) | 一种含有芦荟凝胶的创口修复贴片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230113 |
|
RJ01 | Rejection of invention patent application after publication |